Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07116824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HB1801 Combined Treatment of HER2-positive Breast Cancer

Name: HB1801 Combined Treatment of HER2-positive Breast Cancer — clinical trial record (NCT07116824)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2025-09-15

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 12, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

This study is designed to evaluate the safety and efficacy of HB1801 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic breast cancer.

Trial Details

NCT Number	NCT07116824
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	HER2-positive Breast Cancer
Enrollment	80 participants
Start Date	2025-09-15
Primary Completion	2026-07-15 (estimated)
Study Completion	2027-11-07 (estimated)
Updated on ClinicalTrials.gov	2025-08-12